{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=53", "query": { "condition": "Cancer", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 6203, "total_pages": 621, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=52&page_size=10" }, "source": "local", "last_synced_at": "2026-10-29T11:26:14.109Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07310420", "title": "A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Early Breast Cancer" ], "interventions": [ { "name": "ZOLADEX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TerSera Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 176, "start_date": "2026-10-30", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T07:35:00.276Z", "location_count": 26, "location_summary": "Hot Springs, Arkansas • Washington D.C., District of Columbia • Ocoee, Florida + 23 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07310420" }, { "nct_id": "NCT07291037", "title": "Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Datopotamab deruxtecan (Dato-DXd)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-10-31", "completion_date": "2029-01-29", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-27T21:26:09.529Z", "location_count": 51, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 47 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07291037" }, { "nct_id": "NCT07278557", "title": "Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "MRI sialography", "type": "DEVICE" }, { "name": "Parotid Duct Sparing Radiation Therapy Planning", "type": "OTHER" }, { "name": "Parotid Sparing Radiation Therapy Planning", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2026-01-28", "completion_date": "2030-02", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-16T12:57:13.217Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07278557" }, { "nct_id": "NCT07278336", "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "ABBV-901", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2025-11-27", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T05:12:14.505Z", "location_count": 8, "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07278336" }, { "nct_id": "NCT07206225", "title": "A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "BCG", "type": "DRUG" }, { "name": "PF-02921367", "type": "DRUG" }, { "name": "PF-08052667", "type": "DRUG" }, { "name": "Sasanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2025-11-06", "completion_date": "2033-01-28", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T03:26:11.081Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Ruskin, Florida • Tampa, Florida + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Ruskin", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07206225" }, { "nct_id": "NCT07144280", "title": "A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer Metastatic", "Non-Small Cell Lung Carcinoma", "Non-small Cell Carcinoma" ], "interventions": [ { "name": "Docetaxel monotherapy", "type": "DRUG" }, { "name": "PF-08046054", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2025-09-29", "completion_date": "2032-03-10", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-29T11:26:14.109Z", "location_count": 241, "location_summary": "Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 157 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Bessemer", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07144280" }, { "nct_id": "NCT07128199", "title": "A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adjuvant", "EGFR", "Early Stage Lung Cancer", "Exon 20", "Lung Cancer", "NSCLC, Early Stage", "Post-surgical", "Uncommon EGFR Mutations" ], "interventions": [ { "name": "TAS6417", "type": "DRUG" }, { "name": "Zipalertinib Matching-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-12-22", "completion_date": "2032-10-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-27T14:23:51.424Z", "location_count": 30, "location_summary": "Anchorage, Alaska • Duarte, California • Irvine, California + 26 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07128199" }, { "nct_id": "NCT07090499", "title": "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer", "Advanced/Metastatic Solid Tumors", "Bladder Cancer", "Carcinoma, Non Small Cell Lung", "Carcinoma, Squamous Cell of Head and Neck", "Esophageal Adenocarcinoma", "Esophageal Cancer", "Esophageal Squamous Cell Carcinoma", "Gastroesophageal Junction Adenocarcinoma", "Head and Neck Cancer", "Pancreatic Adenocarcinoma", "Pancreatic Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "PF-08046876", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2025-08-20", "completion_date": "2029-07-08", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-13T20:15:32.703Z", "location_count": 21, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07090499" }, { "nct_id": "NCT07059845", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Mirvetuximab Soravtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 400, "start_date": "2025-11-13", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-13T22:29:19.682Z", "location_count": 31, "location_summary": "La Jolla, California • Solvang, California • Gainesville, Florida + 28 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Solvang", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07059845" }, { "nct_id": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Breast Cancer", "Advanced Solid Tumors" ], "interventions": [ { "name": "ETX-636 dose escalation", "type": "DRUG" }, { "name": "ETX-636 dose escalation in combination with fulvestrant", "type": "DRUG" }, { "name": "ETX-636 dose expansion in combination with fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ensem Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2025-06-10", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-14T11:42:11.232Z", "location_count": 10, "location_summary": "Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06993844" } ] }